Kindstar Globalgene Technology (HKSE:09960) Beneish M-Score: -2.77 (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09960 Kindstar Globalgene Technology Inc HKSE:09960
69 GF Score
Price HK$1.00
GF Value HK$1.06
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Kindstar Globalgene Technology Beneish M-Score?

Kindstar Globalgene Technology HKSE:09960 +3.09% 69 Beneish M-Score is -2.77 as of Aug. 31, 2026. GuruFocus rates HKSE:09960 with a GF Score™ of 69/100 and a GF Value™ of HK$1.06 (Fairly Valued). The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Kindstar Globalgene Technology ranks better than 61.54% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.77 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Kindstar Globalgene Technology's Beneish M-Score or its related term are showing as below:

HKSE:09960' s Beneish M-Score Range Over the Past 10 Years
Min: -5.41   Med: -2.66   Max: -1.56
Current: -2.77

During the past 8 years, the highest Beneish M-Score of Kindstar Globalgene Technology was -1.56. The lowest was -5.41. And the median was -2.66.


Kindstar Globalgene Technology Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Kindstar Globalgene Technology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kindstar Globalgene Technology Beneish M-Score Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -3.93 -1.56 -2.55 -2.14 -2.77

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.55 0.00 -2.14 0.00 -2.77

HKSE:09960 vs TMO, DHR, NTRA: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindstar Globalgene Technology Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's Beneish M-Score falls into.


HKSE:09960
69GF Score
Kindstar Globalgene Technology Inc HKSE:09960
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kindstar Globalgene Technology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Kindstar Globalgene Technology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7822+0.528 * 1.0767+0.404 * 1.2134+0.892 * 1.0414+0.115 * 0.6975
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1081+4.679 * -0.03993-0.327 * 1.026
=-2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$495 Mil.
Revenue was HK$1,031 Mil.
Gross Profit was HK$454 Mil.
Total Current Assets was HK$2,287 Mil.
Total Assets was HK$4,148 Mil.
Property, Plant and Equipment(Net PPE) was HK$653 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$117 Mil.
Selling, General, & Admin. Expense(SGA) was HK$471 Mil.
Total Current Liabilities was HK$815 Mil.
Long-Term Debt & Capital Lease Obligation was HK$254 Mil.
Net Income was HK$-65 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$101 Mil.
Total Receivables was HK$608 Mil.
Revenue was HK$990 Mil.
Gross Profit was HK$469 Mil.
Total Current Assets was HK$2,399 Mil.
Total Assets was HK$4,030 Mil.
Property, Plant and Equipment(Net PPE) was HK$665 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$79 Mil.
Selling, General, & Admin. Expense(SGA) was HK$408 Mil.
Total Current Liabilities was HK$912 Mil.
Long-Term Debt & Capital Lease Obligation was HK$100 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(495.125 / 1031.333) / (607.792 / 990.338)
=0.480083 / 0.613722
=0.7822

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(469.309 / 990.338) / (453.909 / 1031.333)
=0.473888 / 0.440119
=1.0767

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2287.37 + 652.716) / 4147.71) / (1 - (2398.554 + 664.663) / 4030.319)
=0.291154 / 0.239957
=1.2134

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1031.333 / 990.338
=1.0414

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(78.53 / (78.53 + 664.663)) / (116.528 / (116.528 + 652.716))
=0.105666 / 0.151484
=0.6975

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(471.204 / 1031.333) / (408.319 / 990.338)
=0.456888 / 0.412303
=1.1081

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((254.211 + 815.081) / 4147.71) / ((100.381 + 912.267) / 4030.319)
=0.257803 / 0.251258
=1.026

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-64.894 - 0 - 100.722) / 4147.71
=-0.03993

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Kindstar Globalgene Technology has a M-score of -2.77 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.77 mean?
Kindstar Globalgene Technology (HKSE:09960) has a Beneish M-Score of -2.77 as of Aug. 31, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Kindstar Globalgene Technology and its competitors. According to the industry distribution chart, Kindstar Globalgene Technology ranks #75 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 38.5%.
Is Kindstar Globalgene Technology's Beneish M-Score too high?
Kindstar Globalgene Technology's current Beneish M-Score is -2.77. Based on the distribution chart, Kindstar Globalgene Technology ranks #75 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kindstar Globalgene Technology ranks #75 out of 195 companies for Beneish M-Score. This puts Kindstar Globalgene Technology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Kindstar Globalgene Technology and its competitors. Kindstar Globalgene Technology's current Beneish M-Score is -2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current Beneish M-Score is -2.77. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current Beneish M-Score is -2.77 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?

Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued. The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06. GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.

Key valuation signals for HKSE:09960:

  • Beneish M-Score: -2.77
  • GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kindstar Globalgene Technology Business Description

Address Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score

Get the complete analysis for HKSE:09960

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.00
Price
HK$1.06
GF Value